Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Journal of Clinical Microbiology
|
April 29, 2021
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
Maria M Traczewski, Jane E Ambler, Raymond Schuch
Microbiology Spectrum
|
March 2, 2023
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics
Jun Oh, Matthew Warner, Jane E Ambler, et al.
Antimicrobial Agents and Chemotherapy
|
April 27, 2021
Development of a Broth Microdilution Method for Exebacase Susceptibility Testing
Jun T Oh, Jane E Ambler, Cara Cassino, et al.
Antimicrobial Agents and Chemotherapy
|
September 17, 2021
Correction for Oh et al., "Development of a Broth Microdilution Method for Exebacase Susceptibility Testing"
Jun T Oh, Jane E Ambler, Cara Cassino, et al.
The Journal of Antimicrobial Chemotherapy
|
October 31, 2002
Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC)
Fatima Hannachi-M'Zali, Jane E Ambler, Claire F Taylor, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
April 23, 2003
Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation
Stephen H Gillespie, Leroy L Voelker, Jane E Ambler, et al.
The Journal of Antimicrobial Chemotherapy
|
June 6, 2015
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline
Sushmita D Lahiri, Robert E McLaughlin, James D Whiteaker, et al.
Microbiology Spectrum
|
August 10, 2023
Rapid bacteriolysis of <i>Staphylococcus aureus</i> by lysin exebacase
Xavier Vila-Farres, Karen Sauve, Jun Oh, et al.
The Journal of Antimicrobial Chemotherapy
|
November 2, 2017
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model
Renu Singh, Mashal Almutairi, Richard A Alm, et al.
Antimicrobial Agents and Chemotherapy
|
September 30, 2015
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program
Douglas J Biedenbach, Daryl J Hoban, Edina Reiszner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Journal of Clinical Microbiology
|
April 29, 2021
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
Maria M Traczewski, Jane E Ambler, Raymond Schuch
Microbiology Spectrum
|
March 2, 2023
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics
Jun Oh, Matthew Warner, Jane E Ambler, et al.
Antimicrobial Agents and Chemotherapy
|
April 27, 2021
Development of a Broth Microdilution Method for Exebacase Susceptibility Testing
Jun T Oh, Jane E Ambler, Cara Cassino, et al.
Antimicrobial Agents and Chemotherapy
|
September 17, 2021
Correction for Oh et al., "Development of a Broth Microdilution Method for Exebacase Susceptibility Testing"
Jun T Oh, Jane E Ambler, Cara Cassino, et al.
The Journal of Antimicrobial Chemotherapy
|
October 31, 2002
Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC)
Fatima Hannachi-M'Zali, Jane E Ambler, Claire F Taylor, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
April 23, 2003
Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation
Stephen H Gillespie, Leroy L Voelker, Jane E Ambler, et al.
The Journal of Antimicrobial Chemotherapy
|
June 6, 2015
Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline
Sushmita D Lahiri, Robert E McLaughlin, James D Whiteaker, et al.
Microbiology Spectrum
|
August 10, 2023
Rapid bacteriolysis of <i>Staphylococcus aureus</i> by lysin exebacase
Xavier Vila-Farres, Karen Sauve, Jun Oh, et al.
The Journal of Antimicrobial Chemotherapy
|
November 2, 2017
Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model
Renu Singh, Mashal Almutairi, Richard A Alm, et al.
Antimicrobial Agents and Chemotherapy
|
September 30, 2015
In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program
Douglas J Biedenbach, Daryl J Hoban, Edina Reiszner, et al.
Page
of 2